MPLA shows attenuated pro-inflammatory properties and diminished capacity to activate mast cells in comparison with LPS

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 70, Issue 10, 2015, Pages 1259-1268

  Schulke S ^a   Flaczyk, A ^a   Vogel, L ^a   Gaudenzio, N ^b   Angers, I ^c   Loschner B ^a   Wolfheimer, S ^a   Spreitzer, I ^a   Qureshi, S ^c,d   Tsai, M ^b   Galli, S ^b   Vieths, S ^a   Scheurer, S ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

adjuvant; allergy; lipopolysaccharide; mast cells; monophosphoryl lipid A

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PHOSPHORYL LIPID A; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; ANTIGEN; AUTACOID; CYTOKINE; LIPID A; TICAM-1 PROTEIN, MOUSE; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE RELEASE; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VIVO STUDY; MAST CELL; MONOCYTE; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; DENDRITIC CELL; DISEASE MODEL; DRUG EFFECTS; EPITHELIUM CELL; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; SEPTIC SHOCK; TH2 CELL;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; ANTIGENS; B-LYMPHOCYTES; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; HUMANS; INFLAMMATION MEDIATORS; LIPID A; LIPOPOLYSACCHARIDES; MAST CELLS; MICE; MICE, KNOCKOUT; MONOCYTES; SHOCK, SEPTIC; TH2 CELLS;

EID: 84942371618     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12675     Document Type: Article

References (31)

1. Justicia JL, Cardona V, Guardia P, Ojeda P, Olaguíbel JM, Vega JM, et al., Validation of the first treatment-specific questionnaire for the assessment of patient satisfaction with allergen-specific immunotherapy in allergic patients: the ESPIA questionnaire. J Allergy Clin Immunol 2013; 131: 1539-1546.
2. Valenta R,. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002; 2: 446-453.
3. Reed SG, Orr MT, Fox CB,. Key roles of adjuvants in modern vaccines. Nat Med 2013; 19: 1597-1608.
4. Alving CR, Peachman KK, Rao M, Reed SG,. Adjuvants for human vaccines. Curr Opin Immunol 2012; 24: 310-315.
5. Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS,. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine 2011; 29: 9563-9572.
6. Ulrich JT, Myers KR,. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol 1995; 6: 495-524.
7. Cluff CW,. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol 2009; 667: 111-123.
8. Kundi M,. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007; 6: 133-140.
9. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, et al., First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365: 1863-1875.
10. GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, et al., Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374: 1975-1985.
11. Patel P, Salapatek AMF,. Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine. Expert Rev Vaccines 2006; 5: 617-629.
12. Casella CR, Mitchell TC,. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 2008; 65: 3231-3240.
13. Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y, et al., Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003; 33: 1198-1208.
14. Garçon N, Van Mechelen M,. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011; 10: 471-486.
15. Henricson BE, Benjamin WR, Vogel SN,. Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance. Infect Immun 1990; 58: 2429-2437.
16. Casella CR, Mitchell TC, Mata-Haro V, Martin M, Chilton PM, Cekic C, et al., The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007; 316: 1628-1632.
17. Okemoto K, Kawasaki K, Hanada K, Miura M, Nishijima M,. A potent adjuvant monophosphoryl lipid A triggers various immune responses, but not secretion of IL-1beta or activation of caspase-1. J Immunol 2006; 176: 1203-1208.
18. Aybay C, Imir T,. Comparison of the effects of Salmonella minnesota Re595 lipopolysaccharide, lipid A and monophosphoryl lipid A on nitric oxide, TNF-alpha, and IL-6 induction from RAW 264.7 macrophages. FEMS Immunol Med Microbiol 1998; 22: 263-273.
19. Vogel SN, Johnson D, Perera PY, Medvedev A, Larivière L, Qureshi ST, et al., Cutting edge: functional characterization of the effect of the C3H/HeJ defect in mice that lack an Lpsn gene: in vivo evidence for a dominant negative mutation. J Immunol 1999; 162: 5666-5670.
20. Hoffmann S, Peterbauer A, Schindler S, Fennrich S, Poole S, Mistry Y, et al., International validation of novel pyrogen tests based on human monocytoid cells. J Immunol Methods 2005; 298: 161-173.
21. Montag T, Spreitzer I, Löschner B, Unkelbach U, Flory E, Sanzenbacher R, et al., Safety testing of cell-based medicinal products: opportunities for the monocyte activation test for pyrogens. ALTEX 2007; 24: 81-89.
22. Schülke S, Waibler Z, Mende M-S, Zoccatelli G, Vieths S, Toda M, et al., Fusion protein of TLR5-ligand and allergen potentiates activation and IL-10 secretion in murine myeloid DC. Mol Immunol 2010; 48: 341-350.
23. Gaudenzio N, Laurent C, Valitutti S, Espinosa E,. Human mast cells drive memory CD4+ T cells toward an inflammatory IL-22+ phenotype. J Allergy Clin Immunol 2013; 131: 1400-1407.
24. Schülke S, Wolfheimer S, Gadermaier G, Wangorsch A, Siebeneicher S, Briza P, et al., Prevention of intestinal allergy in mice by rflaA: ova is associated with enforced antigen processing and TLR5-dependent IL-10 secretion by mDC. PLoS ONE 2014; 9: e87822.
25. Hill PN, Liu FT,. A sensitive enzyme-linked immunosorbent assay for the quantitation of antigen-specific murine immunoglobulin E. J Immunol Methods 1981; 45: 51-63.
26. Tam S-Y, Tsai M, Snouwaert JN, Kalesnikoff J, Scherrer D, Nakae S, et al., RabGEF1 is a negative regulator of mast cell activation and skin inflammation. Nat Immunol 2004; 5: 844-852.
27. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, et al., AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009; 183: 6186-6197.
28. Röver AC, Reimann S, Zuberbier T, Worm M,. Immunophenotypic characterization of peripheral B cells. During short-term immunotherapy with tree pollen allergoid and the immunoadjuvant monophosphoryl lipid A. J Investig Allergol Clin Immunol 2002; 12: 227-234.
29. Thibult M-L, Mamessier E, Gertner-Dardenne J, Pastor S, Just-Landi S, Xerri L, et al., PD-1 is a novel regulator of human B-cell activation. Int Immunol 2013; 25: 129-137.
30. Ahrens B, Freund T, Rha R-D, Dittrich A-M, Quarcoo D, Hutloff A, et al., Lipopolysaccharide stimulation of dendritic cells induces interleukin-10 producing allergen-specific T cells in vitro but fails to prevent allergic airway disease. Exp Lung Res 2009; 35: 307-323.
31. Keck S, Müller I, Fejer G, Savic I, Tchaptchet S, Nielsen PJ, et al., Absence of TRIF signaling in lipopolysaccharide-stimulated murine mast cells. J Immunol 2011; 186: 5478-5488.